- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05899556
Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients
A Comprehensive View of Patient Experiences of Individuals Participating in Pulmonary Fibrosis Clinical Study
Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what research attributes affect the completion of these specific demographic groups.
This study will admit a wide range of data on the clinical trial experience of pulmonary fibrosis patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future pulmonary fibrosis patients.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Michael B Gill
- Phone Number: 4159004227
- Email: bask@withpower.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- Power Life Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is at least 18 years of age
- Diagnosis of pulmonary fibrosis
- Ability to understand the study procedures, benefits and risks, and sign a written informed consent document.
Exclusion Criteria:
- Enrolled in another research study
- Inability to provide written informed consent
- Women of childbearing potential without a negative pregnancy test; or women who are lactating.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of pulmonary fibrosis patients who decide to participate in a clinical study
Time Frame: 3 months
|
3 months
|
|
Rate of patients who remain in an pulmonary fibrosis clinical study to completion
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Publications and helpful links
General Publications
- Aiello M, Bertorelli G, Bocchino M, Chetta A, Fiore-Donati A, Fois A, Marinari S, Oggionni T, Polla B, Rosi E, Stanziola A, Varone F, Sanduzzi A. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017 Jun;44:7-15. doi: 10.1016/j.pupt.2017.02.005. Epub 2017 Feb 28.
- Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, Reiss AB. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J. 2022 Feb;16(2):84-96. doi: 10.1111/crj.13466. Epub 2022 Jan 10.
- O'Riordan TG, Smith V, Raghu G. Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. Chest. 2015 Oct;148(4):1083-1092. doi: 10.1378/chest.14-3218.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 83217345
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Fibrosis
-
Royal Brompton & Harefield NHS Foundation TrustRecruitingIdiopathic Pulmonary Fibrosis (IPF) | Progressive Pulmonary FibrosisUnited Kingdom
-
Katerina M. AntoniouRecruitingIdiopathic Pulmonary Fibrosis (IPF) | Progressive Pulmonary Fibrosis | Fibrotic Interstitial Lungs DiseasesGreece
-
Huan YeNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)China
-
Henan University of Traditional Chinese MedicineThe First Affiliated Hospital of Zhengzhou University; China-Japan Friendship... and other collaboratorsNot yet recruiting
-
Henan University of Traditional Chinese MedicineThe First Affiliated Hospital of Zhengzhou University; China-Japan Friendship... and other collaboratorsNot yet recruiting
-
Istituto Clinico HumanitasFondazione Policlinico Universitario Agostino Gemelli IRCCS; University of... and other collaboratorsActive, not recruitingIdiopathic Pulmonary Fibrosis (IPF) | Familial Pulmonary Fibrosis | Telomere Disease | Progressive Pulmonary Fibrosis | Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder)Italy
-
Hubei Bio-Pharmaceutical Industrial Technological...Not yet recruiting
-
Beijing Tide Pharmaceutical Co., LtdChina-Japan Friendship HospitalRecruitingIdiopathic Pulmonary Fibrosis (IPF)China
-
Dragonboat Biopharmaceutical Company LimitedRecruitingIdiopathic Pulmonary Fibrosis (IPF)China
-
Regend TherapeuticsNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)China